Synchron has raised a $200 million Series D financing round, which will be used to accelerate commercialization of the company’s first-generation Stentrode BCI platform, while advancing development of a frontier next-generation interface.
The round was led by Double Point Ventures, alongside existing investors ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI and METIS. New investors include the Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT. The financing brings Synchron’s total funding to $345 million.
Synchron’s Stentrode BCI platform is an endovascular brain-computer interface, designed to translate brain activity into digital commands without open-brain surgery. Placed via a non-surgical catheter procedure, the Stentrode interfaces with the motor cortex through the blood vessels, recording and transmitting neural signals wirelessly to enable hands-free control of digital devices. Stentrode BCIs have been placed in 10 patients with paralysis to date, across clinical trials in the U.S. and Australia.
Synchron was the first BCI company to integrate Apple’s BCI-human interface device (BCI-HID), having co-developed a Bluetooth-based iOS protocol that connects brain activity directly to Apple devices using Switch Control, including iPad, iPhone and Vision Pro - no touch, voice, or eye-tracking required.
An expanding Cognitive AI division in New York City will be training models that learn from brain data to decode thought in real time. In parallel, its new San Diego engineering hub has been established to build the world’s most advanced brain interface.
With this Series D financing, Synchron will accelerate pivotal trials, prepare for commercial launch of the Stentrode BCI system, and continue hiring engineers, neuroscientists, and operators to advance the next generation of brain-computer interfaces.
